Bakogeorgou, S.; Filippatos, C.; Malandrakis, P.; Tentolouris, A.; Terpos, E.; Gavriatopoulou, M.; Ntanasis-Stathopoulos, I.
Safety and Efficacy of Bispecific Antibody Treatment in Relapsed/Refractory Multiple Myeloma: A Systematic Review and Meta-Analysis of Proportions from Clinical Trials. Cancers 2025, 17, 2727.
https://doi.org/10.3390/cancers17172727
AMA Style
Bakogeorgou S, Filippatos C, Malandrakis P, Tentolouris A, Terpos E, Gavriatopoulou M, Ntanasis-Stathopoulos I.
Safety and Efficacy of Bispecific Antibody Treatment in Relapsed/Refractory Multiple Myeloma: A Systematic Review and Meta-Analysis of Proportions from Clinical Trials. Cancers. 2025; 17(17):2727.
https://doi.org/10.3390/cancers17172727
Chicago/Turabian Style
Bakogeorgou, Sabrina, Charalampos Filippatos, Panagiotis Malandrakis, Anastasios Tentolouris, Evangelos Terpos, Maria Gavriatopoulou, and Ioannis Ntanasis-Stathopoulos.
2025. "Safety and Efficacy of Bispecific Antibody Treatment in Relapsed/Refractory Multiple Myeloma: A Systematic Review and Meta-Analysis of Proportions from Clinical Trials" Cancers 17, no. 17: 2727.
https://doi.org/10.3390/cancers17172727
APA Style
Bakogeorgou, S., Filippatos, C., Malandrakis, P., Tentolouris, A., Terpos, E., Gavriatopoulou, M., & Ntanasis-Stathopoulos, I.
(2025). Safety and Efficacy of Bispecific Antibody Treatment in Relapsed/Refractory Multiple Myeloma: A Systematic Review and Meta-Analysis of Proportions from Clinical Trials. Cancers, 17(17), 2727.
https://doi.org/10.3390/cancers17172727
